
    
      All eligible patients will receive immunotherapy (Nivolumab) plus radiotherapy, 6 Gy x 5
      fractions, to a targetable lesion. Immunotherapy treatment starts with the first radiotherapy
      fraction. Nivolumab will be given every 2 weeks. Patients will have specified laboratory
      values measured bi-monthly and evaluated for response at 12 weeks as defined by International
      Myeloma Working Group Criteria. Patients will continue to receive their respective
      immunotherapy until disease progression or dose limiting toxicity is reached.
    
  